


PD173952

Cat. No.:	HY-122113		
CAS No.:	305820-75-1		
Molecular Formula:	C ₂₄ H ₂₁ Cl ₂ N ₅ O ₂		
Molecular Weight:	482.36		
Target:	Src; Bcr-Abl; Apoptosis; Wee1		
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis; Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	PD173952 is a tyrosine kinases inhibitor with IC ₅₀ s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a K _i of 8.1 nM. PD173952 induces apoptosis ^{[1][2]} .																					
IC₅₀ & Target	Lyn 0.3 nM (IC ₅₀)	Abl 1.7 nM (IC ₅₀)	Csk 6.6 nM (IC ₅₀)	Myt1 8.1 nM (K _i)																		
In Vitro	<p>PD173952 (0-1000 nM; 12 h) inhibits tyrosine phosphorylation of p210^{Bcr-Abl} and CrkL in K562 cells in a concentration-dependent manner^[1].</p> <p>PD173952 (0.5 μM; 1-4 days) inhibits K562 cell viability^[1].</p> <p>PD173952 (0.5 μM; 24 and 48 h) induces apoptosis of K562 and MEG-01 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 25, 50, 100, 200, 500 and 1000 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>12 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited tyrosine phosphorylation of p210^{Bcr-Abl} and CrkL.</td> </tr> </table> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1-4 days</td> </tr> <tr> <td>Result:</td> <td>Caused cell death in a time-dependent manner.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 and MEG-01 cells</td> </tr> </table>				Cell Line:	K562 cells	Concentration:	0, 25, 50, 100, 200, 500 and 1000 nM	Incubation Time:	12 h	Result:	Inhibited tyrosine phosphorylation of p210 ^{Bcr-Abl} and CrkL.	Cell Line:	K562 cells	Concentration:	0.5 μM	Incubation Time:	1-4 days	Result:	Caused cell death in a time-dependent manner.	Cell Line:	K562 and MEG-01 cells
Cell Line:	K562 cells																					
Concentration:	0, 25, 50, 100, 200, 500 and 1000 nM																					
Incubation Time:	12 h																					
Result:	Inhibited tyrosine phosphorylation of p210 ^{Bcr-Abl} and CrkL.																					
Cell Line:	K562 cells																					
Concentration:	0.5 μM																					
Incubation Time:	1-4 days																					
Result:	Caused cell death in a time-dependent manner.																					
Cell Line:	K562 and MEG-01 cells																					

Concentration:	0.5 μ M
Incubation Time:	24 and 48 h
Result:	85-kDa PARP fragment was detected.

REFERENCES

[1]. Dorsey JF, et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. *Leukemia*. 2002 Sep;16(9):1589-95.

[2]. Wichapong K, et al. Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. *J Chem Inf Model*. 2014 Mar 24;54(3):881-93.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA